What if aging is not a collection of diseases, but a system-level failure we can intervene in?

In this episode of Galaxy Balance, Cory Smith sits down with Noah Davidsohn, co-founder and CSO of Rejuvenate Bio, to explore a new approach to longevity rooted in gene therapy and systems biology.

Noah’s work focuses on treating aging at its source by rebalancing key biological pathways across the body. Instead of targeting one disease at a time, his team is developing combination gene therapies designed to improve function across multiple organs simultaneously.

Rejuvenate Bio is currently raising on Wefunder. This is a rare opportunity to invest in a scaling biotech on the same terms as their VC partners. If our conversation resonated with you, this is your chance to join what Dr. Noah Davidsohn is building. Learn more and invest at wefunder.com/rejuvenatebio

00:00 - Replacing organs to reverse aging: science fiction or imminent reality

00:34 - Welcome to Galaxy Balance: exploring biology and AI frontiers

01:01 - Noah Davidson’s background and mission at Rejuvenate Bio

01:57 - Reprogramming biological systems for systemic healthspan extension

02:41 - The influence of sci-fi on Noah’s interest in space and longevity

03:38 - Space exploration's crossover with biological resilience

05:25 - The societal impact of science fiction on technological progress

07:55 - Addressing dystopian themes in modern sci-fi and their societal reflection

08:16 - The absence of longevity-focused sci-fi and Noah’s motivation

09:12 - Personal story: pet dog inspired Noah’s longevity work

10:33 - Origin of Rejuvenate Bio and its mission to treat aging

11:57 - Combining gene therapies targeting multiple age-related diseases

13:44 - The potential and limitations of epigenetic partial reprogramming

14:14 - Upcoming clinical trials and safety considerations for gene therapy

16:01 - Cyclic gene therapy and risks of permanent expression

17:43 - Inducible gene expression systems: safety and practical considerations

21:19 - Systemic, liver-targeted gene therapies: permanent vs. transient

22:33 - Strategies for pet therapies and expanding to human applications

25:47 - Manufacturing innovations reducing costs for wide-scale treatment

27:12 - Prophylactic use of gene therapies in pets and humans

29:08 - Targeting multiple diseases with a single systemic therapy

30:40 - Breeds at risk for mitral valve disease and targeted therapy efforts

33:42 - Disease-modifying treatments for fibrosis and heart failure

36:48 - How AAV vector delivery works and safety measures in tissue targeting

42:47 - Regulatory pathways for animal therapies and translational relevance

44:22 - Challenges in funding and VC environment for longevity startups

45:45 - The strategy of using animal models as a bridge to human therapies

50:05 - Future scientific directions: partial reprogramming and cell replacement tech

52:37 - The concept of longevity escape velocity and current progress

53:44 - Personal longevity practices: exercise, diet, sleep, stress management

55:27 - The role of biometric feedback devices in health monitoring

56:54 - Emerging modalities and innovative approaches in anti-aging research

58:24 - The ship of Theseus analogy for cell and tissue replacement

59:37 - Philosophical questions about consciousness and identity in aging

1:00:43 - Recommended sci-fi books for longevity and biotech enthusiasts

1:01:39 - Career advice for aspiring scientists and interdisciplinary innovation

1:02:45 - Wrap-up and best wishes for ongoing longevity breakthroughs